Eli Lilly & Co. remains conspicuously absent from the Dow 30, despite briefly topping a $1 trillion market cap on November 21, 2025, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound. The exclusion is attributed to the Dow's price-weighted nature, which a $1,000+ share price would overwhelm, sector balance, and narrative fit, according to a December 08, 2025 analysis. LLY closed at $997.72 on December 08, 2025, down 0.16% in after-hours trading.